Brentuximab is used to treat certain types of cancers (Hodgkin’s lymphoma, systemic anaplastic large cell lymphoma, primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides). It works by slowing or stopping the growth of cancer cells.
What Adcetris is and what it is used for
Adcetris contains the active substance brentuximab vedotin, an anti-cancer agent, which is made up of a monoclonal antibody linked to a substance intended to kill cancer cells. This substance is delivered to cancer cells by the monoclonal antibody. A monoclonal antibody is a protein which recognises certain cancer cells.
Adcetris is used to treat classical Hodgkin lymphoma that has:
come back after or not responded to an infusion of your own healthy stem cells into your body (autologous stem cell transplant), or
come back after or never responded to at least two previous therapies, and where you cannot receive additional combination anti-cancer treatments or have an autologous stem cell transplant.
Classical Hodgkin lymphoma expresses specific proteins on the cell surface that are different from non-classical Hodgkin lymphoma.
Adcetris is also used to lower the likelihood of classical Hodgkin Lymphoma coming back after an autologous stem cell transplant in patients with certain risk factors.
Adcetris is used to treat systemic anaplastic large cell lymphoma which is found in your lymph nodes and/or throughout other parts of your body that has:
not responded to other types of anti-cancer treatments, or
come back after previous anti-cancer treatment.
Hodgkin lymphoma and systemic anaplastic large cell lymphoma are both types of cancer of the white blood cells.
Adcetris is used to treat cutaneous T-cell lymphoma (CTCL) in patients who have previously received at least one medicine that travels through the bloodstream.
CTCL is a cancer of a certain type of white blood cell called a ‘T-cell’ that mainly affects the skin. Adcetris is used to treat CTCL where a specific type of protein is present on the cells’ surface.